Wednesday, July 8, 2026
🇺🇸 FDA

pharma · Cocaine-Related Disorders · Cocaine Dependence · DRUG

BRIGHT MINDS BIOSCIENCES

BRIGHT MINDS BIOSCIENCES INC.

BRIGHT MINDS BIOSCIENCES clinical programs — 393 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
19 Vestry St, New York, NY 10013, US HQ
12 Employees
Public company Type
DRUG · NYSE Ticker
Company details
Status
Public
HQ
19 Vestry St, New York, NY 10013, US
Employees
12
Programs
1063
Drugs
444
Patents
57
Official website ↗ All projects Drug pipeline Patents News & analysis
Intelligence · Clinical Programs

BRIGHT MINDS BIOSCIENCES projects

393 ClinicalTrials.gov programs sponsored by BRIGHT MINDS BIOSCIENCES.

BRIGHT MINDS BIOSCIENCES has 393 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

393 programs

Clinical programs

Page 2 of 9

  1. Bupropion

    BRIGHT MINDS BIOSCIENCES INC.

    Marijuana Abuse

    phase 2 small molecule completed

    1 trial

  2. Bupropion

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Dependence

    phase 2 small molecule completed

    1 trial

  3. Bupropion

    BRIGHT MINDS BIOSCIENCES INC.

    Amphetamine-Related Disorders

    phase 2 small molecule active

    2 trials

  4. Bupropion

    BRIGHT MINDS BIOSCIENCES INC.

    Schizophrenia and Disorders With Psychotic Features

    phase 2 small molecule completed

    1 trial

  5. Bupropion SR 150mg tabs

    BRIGHT MINDS BIOSCIENCES INC.

    Adolescent Methamphetamine Abuse

    phase 2 small molecule completed

    1 trial

  6. Bupropion and NRT

    BRIGHT MINDS BIOSCIENCES INC.

    Tobacco Use Disorder

    phase 2 small molecule completed

    1 trial

  7. Buspirone

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Dependence

    phase 2 small molecule completed

    1 trial

  8. CAM2038

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid-use Disorder

    phase 2 small molecule completed

    1 trial

  9. CDC-NCHSTP-4448

    BRIGHT MINDS BIOSCIENCES INC.

    Tuberculosis

    phase 2 small molecule completed

    1 trial

  10. CERC-501

    BRIGHT MINDS BIOSCIENCES INC.

    Smoking

    phase 2 small molecule completed

    1 trial

  11. CET/PT

    BRIGHT MINDS BIOSCIENCES INC.

    Schizophrenia

    phase 2 other completed

    1 trial

  12. CHRMS19-0129

    BRIGHT MINDS BIOSCIENCES INC.

    Tobacco Use Disorder

    phase 2 other completed

    1 trial

  13. CI-581aa

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid Dependence

    phase 2 small molecule completed

    1 trial

  14. CRAFT-T

    BRIGHT MINDS BIOSCIENCES INC.

    Heroin Dependence

    phase 2 other active

    1 trial

  15. CYB003

    BRIGHT MINDS BIOSCIENCES INC.

    Major Depressive Disorder

    phase 2 small molecule completed

    1 trial

  16. Caffeine 150 MG

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Dependence

    phase 2 small molecule completed

    1 trial

  17. Caffeine citrate

    BRIGHT MINDS BIOSCIENCES INC.

    Retinopathy of Prematurity

    phase 2 small molecule completed

    1 trial

  18. Candesartan with CBT

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Dependence

    phase 2 small molecule terminated

    1 trial

  19. Cannabidiol

    BRIGHT MINDS BIOSCIENCES INC.

    Radiculopathy

    phase 2 small molecule completed

    1 trial

  20. Cannabidiol (CBD) 600 mg

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid-use Disorder

    phase 2 small molecule completed

    1 trial

  21. Cannabidiol - fsCBD

    BRIGHT MINDS BIOSCIENCES INC.

    Cannabis Use Disorder

    phase 2 small molecule active

    1 trial

  22. Cannabis

    BRIGHT MINDS BIOSCIENCES INC.

    Cannabis Use

    phase 2 small molecule active

    2 trials

  23. Cariprazine Oral Capsule [Vraylar]

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Use Disorder

    phase 2 small molecule terminated

    1 trial

  24. Carvedilol

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine-Related Disorders

    phase 2 small molecule completed

    1 trial

  25. Ceremony

    BRIGHT MINDS BIOSCIENCES INC.

    Substance Use

    phase 2 other active

    1 trial

  26. Chantix

    BRIGHT MINDS BIOSCIENCES INC.

    Nicotine Dependence

    phase 2 small molecule terminated

    2 trials

  27. Cigarettes with varying nicotine content

    BRIGHT MINDS BIOSCIENCES INC.

    Tobacco Use Disorder

    phase 2 other completed

    1 trial

  28. Citalopram

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Dependence

    phase 2 small molecule completed

    3 trials

  29. Clonazepam

    BRIGHT MINDS BIOSCIENCES INC.

    REM Sleep Behavior Disorder

    phase 2 small molecule completed

    1 trial

  30. Clonazepam

    BRIGHT MINDS BIOSCIENCES INC.

    Cannabis Use Disorder

    phase 2 small molecule completed

    1 trial

  31. Clonidine

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid-Related Disorders

    phase 2 small molecule completed

    1 trial

  32. Cognitive Behavioral Intervention

    BRIGHT MINDS BIOSCIENCES INC.

    Substance Abuse

    phase 2 other completed

    1 trial

  33. Cognitive Behavioral Therapy (CBT)

    BRIGHT MINDS BIOSCIENCES INC.

    Stress Disorders, Post Traumatic

    phase 2 other completed

    1 trial

  34. Combined intervention

    BRIGHT MINDS BIOSCIENCES INC.

    Tobacco Use Disorder

    phase 2 other completed

    1 trial

  35. Community Reinforcement Approach (CRA) + HIV prevention

    BRIGHT MINDS BIOSCIENCES INC.

    Substance Abuse

    phase 2 other completed

    1 trial

  36. Computer-based Motivational Interviewing

    BRIGHT MINDS BIOSCIENCES INC.

    Substance Abuse

    phase 2 other completed

    1 trial

  37. Computer-delivered brief intervention (5As)

    BRIGHT MINDS BIOSCIENCES INC.

    Smoking

    phase 2 other completed

    1 trial

  38. Computerized cognitively stimulating activities

    BRIGHT MINDS BIOSCIENCES INC.

    Substance Use Disorders

    phase 2 other completed

    1 trial

  39. Computerized tasks

    BRIGHT MINDS BIOSCIENCES INC.

    Substance Use Disorders

    phase 2 other completed

    1 trial

  40. Contingency Management-Family Engagement (CM-FAM)

    BRIGHT MINDS BIOSCIENCES INC.

    Adolescent Substance Use

    phase 2 other completed

    1 trial

  41. Coreg

    BRIGHT MINDS BIOSCIENCES INC.

    Anxiety

    phase 2 small molecule terminated

    1 trial

  42. Cotinine fumarate

    BRIGHT MINDS BIOSCIENCES INC.

    Tobacco Use Disorder

    phase 2 small molecule completed

    2 trials

  43. Cycloserine

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid-Related Disorders

    phase 2 small molecule terminated

    1 trial

  44. D-Amphetamine 30mg

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine-Related Disorders

    phase 2 small molecule completed

    1 trial

  45. D-Cycloserine

    BRIGHT MINDS BIOSCIENCES INC.

    Smoking Cessation

    phase 2 small molecule terminated

    1 trial

  46. D-Cycloserine (DCS)

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Use Disorders

    phase 2 small molecule completed

    1 trial

  47. D-cycloserine

    BRIGHT MINDS BIOSCIENCES INC.

    Substance-Related Disorders

    phase 2 small molecule terminated

    1 trial

  48. Decoy20

    BRIGHT MINDS BIOSCIENCES INC.

    Solid Tumor, Adult

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does BRIGHT MINDS BIOSCIENCES have?

393 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.